OLK
Olink Holding AB (publ)
stock NASDAQ

#
**Investment Thesis:**
Quantum-Si is building what could be the first widely adopted protein sequencing platform, a breakthrough that has the potential to do for proteomics what Illumina did for genomics. The company has successfully launched its Platinum® system, is actively placing instruments at leading research institutions, and has begun building the high-margin consumables revenue stream that is the backbone of every successful life sciences tools company. With a strong balance sheet that extends well past 2027, QSI has the time and resources to execute. The upcoming **Investor & Analyst Day on November 19, 2025** is the next major catalyst, where management is expected to highlight adoption trends, product roadmap, and customer traction. We believe the stock has meaningful upside into and after this event.
# Why Quantum-Si Can Succeed
# 1. Technology Advantage – True Protein Sequencing
* Unlike competitors focused on incremental improvements in proteomics, Quantum-Si is pioneering **single-molecule protein sequencing**, allowing researchers to see the proteome with unprecedented detail compared to competitors like $SEER, $OLK and Somalogic.
* This positions QSI in the same disruptive category that Illumina was in the early days of next-gen sequencing. If adoption accelerates, the company’s consumables-driven model could scale rapidly.
# 2. Commercial Launch & Early Placements
* The **Platinum® and Platinum Pro systems** are already in the field, with notable placements including top-tier institutions like the **Broad Institute**. This is a crucial credibility signal and an early indicator of broader adoption potential.
* Product launches have been consistent, with new kits and library prep tools hitting the market, demonstrating that the platform is maturing and management is delivering against the roadmap.
# 3. Cash Position = Long Runway
* As of Q1 2025, Quantum-Si held **over $230 million in cash and securities**, and recent financing has pushed the runway comfortably into **2027–2028**.
* This removes the near-term financing overhang that plagues many small-cap life sciences names, allowing management to focus on execution and commercialization without dilution pressure.
# 4. Upcoming Catalyst – November 19 Investor & Analyst Day
* Management has scheduled an in-depth investor event in NYC. These events are designed to showcase:
* Updated **instrument placements and installed base** growth.
* Early **consumables revenue trajectory** (the key driver of margins).
* Case studies from reference customers and independent validation data.
* A clear **roadmap** for the Proteus platform and future products.
* With QSI’s stock trading at a depressed valuation, any evidence of commercial traction or stronger-than-expected adoption could drive a material re-rating. **(In case anyone is unsure, the 50mil offering done by an unknown investor (partner) will be revealed here. There are ALOT of rumors floating around that it is Nvidia and if this is proven true, this is an instant moonshot to $10 and above.**
# Why the Timing is Attractive
* **Set-up:** The stock is trading near all-time lows, implying little credit for the technology or long runway. This sets the stage for asymmetric upside if the company delivers a convincing update in November.
* **Runway to catalyst:** QSI has several months to build momentum through product launches, placements, and publications that can be highlighted at the event. Each incremental news release strengthens the bull case going into November.
* **Investor psychology:** Investor Days are often overlooked until after they happen. If QSI demonstrates a step-change in adoption metrics, the stock could see a sharp re-rating as the market wakes up to its potential.
# Bottom Line
Quantum-Si is not just another small-cap life sciences tools company since it’s an early leader in a field that could redefine how we study biology. The company has cash, a differentiated technology, early validation, and now a visible catalyst in the **November 19 Investor & Analyst Day**. At current levels, the market is discounting the probability of success far too heavily. We see meaningful upside as execution continues and expect the November event to mark a turning point in the QSI story.
**Positioning:** Accumulate shares ahead of the November 19 event, with a view of positive adoption updates and a reinforced commercial roadmap.
**Edit:** This company may soon be in the midst of a huge buy-out opportunity with its recent movement despite having >200million cash runway into 2028. They have recently stopped their lease with their office rental (paid $11million to cancel it) and had a $300 million shelf even with so much cash on hand (which signifies cleaning up of balance sheet). Look up SEC filings. ***Estimated price from buyout is at the minimum $5*** based on analysis & November will be the biggest catalyst for this firm till date. There is a **HUGE chance** that in November, the company may announce its acquisition or with a big strategic partner.

#
**Investment Thesis:**
Quantum-Si is building what could be the first widely adopted protein sequencing platform, a breakthrough that has the potential to do for proteomics what Illumina did for genomics. The company has successfully launched its Platinum® system, is actively placing instruments at leading research institutions, and has begun building the high-margin consumables revenue stream that is the backbone of every successful life sciences tools company. With a strong balance sheet that extends well past 2027, QSI has the time and resources to execute. The upcoming **Investor & Analyst Day on November 19, 2025** is the next major catalyst, where management is expected to highlight adoption trends, product roadmap, and customer traction. We believe the stock has meaningful upside into and after this event.
# Why Quantum-Si Can Succeed
# 1. Technology Advantage – True Protein Sequencing
* Unlike competitors focused on incremental improvements in proteomics, Quantum-Si is pioneering **single-molecule protein sequencing**, allowing researchers to see the proteome with unprecedented detail compared to competitors like $SEER, $OLK and Somalogic.
* This positions QSI in the same disruptive category that Illumina was in the early days of next-gen sequencing. If adoption accelerates, the company’s consumables-driven model could scale rapidly.
# 2. Commercial Launch & Early Placements
* The **Platinum® and Platinum Pro systems** are already in the field, with notable placements including top-tier institutions like the **Broad Institute**. This is a crucial credibility signal and an early indicator of broader adoption potential.
* Product launches have been consistent, with new kits and library prep tools hitting the market, demonstrating that the platform is maturing and management is delivering against the roadmap.
# 3. Cash Position = Long Runway
* As of Q1 2025, Quantum-Si held **over $230 million in cash and securities**, and recent financing has pushed the runway comfortably into **2027–2028**.
* This removes the near-term financing overhang that plagues many small-cap life sciences names, allowing management to focus on execution and commercialization without dilution pressure.
# 4. Upcoming Catalyst – November 19 Investor & Analyst Day
* Management has scheduled an in-depth investor event in NYC. These events are designed to showcase:
* Updated **instrument placements and installed base** growth.
* Early **consumables revenue trajectory** (the key driver of margins).
* Case studies from reference customers and independent validation data.
* A clear **roadmap** for the Proteus platform and future products.
* With QSI’s stock trading at a depressed valuation, any evidence of commercial traction or stronger-than-expected adoption could drive a material re-rating. **(In case anyone is unsure, the 50mil offering done by an unknown investor (partner) will be revealed here. There are ALOT of rumors floating around that it is Nvidia and if this is proven true, this is an instant moonshot to $10 and above.**
# Why the Timing is Attractive
* **Set-up:** The stock is trading near all-time lows, implying little credit for the technology or long runway. This sets the stage for asymmetric upside if the company delivers a convincing update in November.
* **Runway to catalyst:** QSI has several months to build momentum through product launches, placements, and publications that can be highlighted at the event. Each incremental news release strengthens the bull case going into November.
* **Investor psychology:** Investor Days are often overlooked until after they happen. If QSI demonstrates a step-change in adoption metrics, the stock could see a sharp re-rating as the market wakes up to its potential.
# Bottom Line
Quantum-Si is not just another small-cap life sciences tools company since it’s an early leader in a field that could redefine how we study biology. The company has cash, a differentiated technology, early validation, and now a visible catalyst in the **November 19 Investor & Analyst Day**. At current levels, the market is discounting the probability of success far too heavily. We see meaningful upside as execution continues and expect the November event to mark a turning point in the QSI story.
**Positioning:** Accumulate shares ahead of the November 19 event, with a view of positive adoption updates and a reinforced commercial roadmap.
**Edit:** This company may soon be in the midst of a huge buy-out opportunity with its recent movement despite having >200million cash runway into 2028. They have recently stopped their lease with their office rental (paid $11million to cancel it) and had a $300 million shelf even with so much cash on hand (which signifies cleaning up of balance sheet). Look up SEC filings. ***Estimated price from buyout is at the minimum $5*** based on analysis & November will be the biggest catalyst for this firm till date. There is a **HUGE chance** that in November, the company may announce its acquisition or with a big strategic partner.